Evidence map›Paper›PMID 37007125›Full record

ReviewFrontiers in oncology2023

A key driver to promote HCC: Cellular crosstalk in tumor microenvironment.

Pengyue Liu, Lingyu Kong, Ying Liu, Gang Li, Jianjia Xie, Xin Lu

Open access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Pengyue LiuClinical Medical College, North China University of Science and Technology, Tangshan, China.
Lingyu KongDepartment of Traditional Chinese Medicine, Affiliated Hospital of North China University of Science and Technology, Tangshan, China.
Ying LiuDepartment of Clinical Skills Training Center, Tangshan Gongren Hospital, Tangshan, China.
Gang LiDepartment of Clinical Laboratory, Tangshan Maternal and Child Health Care Hospital, Tangshan, China.
Jianjia XieDepartment of Clinical Laboratory, Tangshan Maternal and Child Health Care Hospital, Tangshan, China.
Xin LuClinical Medical College, North China University of Science and Technology, Tangshan, China.
Tangshan People's Hospital · CNNorth China University of Science and Technology · CNTangshan Gongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is the third greatest cause of cancer-related mortality, which of the major pathological type is hepatocellular carcinoma (HCC) accounting for more than 90%. HCC is characterized by high mortality and is predisposed to metastasis and relapse, leading to a low five-year survival rate and poor clinical prognosis. Numerous crosstalk among tumor parenchymal cells, anti-tumor cells, stroma cells, and immunosuppressive cells contributes to the immunosuppressive tumor microenvironment (TME), in which the function and frequency of anti-tumor cells are reduced with that of associated pro-tumor cells increasing, accordingly resulting in tumor malignant progression. Indeed, sorting out and understanding the signaling pathways and molecular mechanisms of cellular crosstalk in TME is crucial to discover more key targets and specific biomarkers, so that develop more efficient methods for early diagnosis and individualized treatment of liver cancer. This piece of writing offers insight into the recent advances in HCC-TME and reviews various mechanisms that promote HCC malignant progression from the perspective of mutual crosstalk among different types of cells in TME, aiming to assist in identifying the possible research directions and methods in the future for discovering new targets that could prevent HCC malignant progression.

Indexed as

cellular crosstalkhepatocellular carcinoma (HCC)tumor immunosuppressiontumor malignant progressiontumor microenvironment (TME)

Identifiers

PMID37007125
PMCPMC10050394
OpenAlexW4324376026

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.